Back in 2014, AstraZeneca and Merck were the first to receive FDA approval for their PARP inhibitor Lynparza (olaparib) for use in breast cancer gene (BRCA)-mutated metastatic ovarian cancer patients.
Celularity, a biotech company specializing in placental-derived allogeneic cell therapies, will be showcasing data at the upcoming ASGCT Annual Meeting, showcasing the potential of their off-the-shelf natural killer (NK) cells to combat age-related diseases....
‘Chemo mouth’, otherwise known as oral mucositis, has emerged as the most significant adverse event in oncology, according to a National Comprehensive Cancer Network task force.
Molecure S.A., a leading biotechnology company focused on drug discovery and development, has unveiled its annual report for 2023 at the start of the new financial year.
Ipsen is expanding its oncology pipeline by securing the global licensing rights to an antibody-drug conjugate (ADC) for solid tumors from Sutro Biopharma, its first drug in the category.
From math hater to a leader in clinical data, it’s been a long journey for Jennifer Visser-Rogers, vice president for statistical research and consultancy at Phastar.
Curve Therapeutics, a biotech pioneering an intracellular screening platform addressing complex and challenging disease targets, has announced the publication of an article in the Journal of the American Chemical Society (JACS).
AstraZeneca recently announced its £650 million investment in the UK, held up by Chancellor Jeremy Hunt as a ‘vote of confidence’ in the country’s life sciences sector.
Bristol Myers Squibb’s Opdivo was recently granted FDA approval in combination with cisplatin and gemcitabine as a first-line treatment for metastatic urothelial carcinoma (mUC).
One of the most challenging aspects of the COVID-19 pandemic was not being able to assess how individual patients would respond to the virus and how severe their symptoms would be.
SolasCure is moving forward with its maggot-derived wound gel, after publishing the results of its recent phase 2 clinical trial in a leading wound care journal.
Mandziuk is vice president, project management, eClinical Development & Delivery, at ICON and she says nothing could have prepared the health industry for the global impact the Covid pandemic has had.
Baseimmune, a biotech company that uses proprietary, deep learning AI to predict future pathogen mutations to generate novel vaccines, has closed its $11.3 million Series A funding round.
Japanese pharmaceutical company Shionogi has announced the first peer-reviewed publication of its phase 3 study investigating ensitrelvir to treat patients with mild to moderate COVID-19 in Japan, South Korea and Vietnam.
Sano Chemicals has begun its phase 1, first-in-human clinical trial of Occidiofungin, a new treatment to cure recurrent vaginal yeast infections or vulvovaginal candidiasis (RVVC).
Dermatology biopharma company Arcutis has launched ZORYVE, a topical foam for the treatment of seborrheic dermatitis, in the United States for individuals 9 years of age and older.
Despite the current Bruton tyrosine kinase (BTK) inhibitor market being valued at approximately $6 billion, sales specifically for chronic lymphocytic leukemia (CLL) are predicted to be nearly $5 billion by 2032 in the seven major markets.
The Cell and Gene Therapy Catapult (CGT Catapult), an independent organization specialising in the advancement of cell and gene therapies, has revealed that the UK has remained an attractive destination for commercial trials, with this type of clinical...
A £30 million ($38 million) study into liver cirrhosis, the most extensive ever conducted worldwide has been announced by Newcastle University and University of Edinburgh, funded by Boehringer Ingelheim.
MaaT Pharma, a clinical-stage biotech company developing microbiome ecosystem therapies, has presented positive results from a recent study investigating its lead product MaaT013 for patients with steroid-refractory (SR) or steroid-dependent (SD) gastrointestinal...
Candel Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its lead adenovirus asset CAN-2409, for the treatment of pancreatic cancer.
UK-based Lindus Health and US-based Thirty Madison today (December 14) announced they have completed the enrolment of a trial to assess their personalized dermatology telemedicine platform, Facet.
PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), has received approval to continue its BIOPATTERN trial following recruitment of the first ten patients with CAD.
Outsourcing Pharma is delighted to invite you to join our not-to-be-missed webinar on one of the most important areas of the industry – patient centricity – and its solutions.
Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are common in solid tumors, including lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma.
At the American Heart Association (AHA) Scientific Sessions 2023 in Philadelphia, Arrowhead Pharmaceuticals unveiled the phase 2 clinical data for plozasiran (ARO-APOC3) and zodasiran (ARO-ANG3).
Cellipoint Bioservices signed an agreement with Diakonos Oncology in October 2023 for the development and manufacturing of DOC1021, an autologous dendritic cell (DC) vaccine.
Accessing various sponsor technology systems in a clinical trial can be a laborious and complex process. Site vendors often have to juggle various links and platforms to access important information and manage large lists of credentials across studies...
Antiverse, a biotech company developing a computational antibody drug discovery platform, is extending its collaboration with GlobalBio, an antibody engineering company, to advance immune checkpoint inhibitors in cancer therapy.
In our first podcast interview of 2023, BioPharma Reporter spoke with Dr Sarah Bateup, therapy lead at Clerkenwell Health, about the potential of psychedelic medicine and her work within the psychedelic therapy training space.
BPGbio, an AI-powered biopharma that focuses on oncology, neurology, and rare diseases, is advancing its pancreatic cancer drug BPM 31510 IV after a positive phase 1 and 2a study.
Mount Sinai investigators have developed a new approach for treating invasive bladder cancer without the need for surgical removal of the bladder, according to a study published in Nature Medicine in September.
The Novo Nordisk Foundation is planning to build a €127 million ($135 million) facility in Denmark to speed up the development and manufacturing process for cell therapies for use in early clinical trials.
Global biopharmaceutical company Takeda is working to modernize its operations in order to better serve clinical trial sites, patients and sponsor outcomes.
GEDiCube is joining NVIDIA Inception, a program which guides start-ups by providing access to cutting-edge technology, technical resources, and venture capitalists.
Liz Beatty is co-founder and chief strategy officer at Inato, a clinical trials platform which flips the traditional model and allows community sites to participate in the trials that are best aligned with their interests and that of their patients.
The first and only approved anti-amyloid Alzheimer's Disease (AD) treatment shown to reduce the rate of disease progression and slow cognitive impairment has been granted approval by the FDA.
Katherine Vega Stultz is the CEO and president of Ocelot Bio, a clinical-stage biotech company focused on the development of therapeutics to treat complications of end-stage liver disease.
Shionogi has enrolled the first participant in Japan in its phase 3 clinical trial of oral antiviral ensitrelvir to stop the post-infection progression of Covid-19.
BenevolentAI, a clinical-stage AI development company, has announced the successful delivery of its pre-clinical candidate for the potential treatment of amyotrophic lateral sclerosis (ALS), BEN-34712.
TILT Biotherapeutics, a biotech company developing cancer immunotherapies, has announced that the first patient has been dosed in a phase 1 trial of the company’s oncolytic adenovirus TILT-123.
The South Korean company is set to create a new facility in West Virginia to house insulin manufacturing and to deliver its insulin products in the country.
Breath biopsy specialist, Owlstone Medical, has entered into a research agreement with biotech company, Bicycle Therapeutics plc, to access its bicyclic peptide technology.
The US biotech CytomX has lost a collaboration partner as AbbVie pulled out of a collaboration developing an antibody-drug conjugate (ADC) for the treatment of solid tumours.
Switzerland headquartered Lonza said it is expanding its early development services (EDS) to North America, opening a new laboratory in Cambridge, Massachusetts (US).
Amgen joins the Winn Award Program that was set up by Bristol Myers Squibb, with plans to extend the reach of clinical trials into underserved patient populations in the US.
Pyxis Oncology has received clearance for two IND applications from the US Food and Drug Administration (FDA) to initiate two Phase 1 clinical studies.
